Mosunetuzumab Subcutaneous Dosing Patent Application for B Cell Disorders
Summary
The USPTO has published patent application US20260109777A1, filed June 25, 2025 (Application No. 19249597), titled 'Methods of Treating Cancer Using Subcutaneous Dosing of Mosunetuzumab as a Monotherapy or in Combination with Lenalidomide.' The application covers methods for treating CD20-positive B cell proliferative disorders including non-Hodgkin's lymphomas and chronic lymphocytic leukemia via subcutaneous administration of mosunetuzumab, alone or combined with lenalidomide. Named inventors include Samuel Dean Tracy, Hong Wang, Jue Wang, Brendan Christian Bender, and 13 others. This published application represents an early-stage intellectual property filing and does not yet constitute an issued patent grant.
“The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas or chronic lymphocytic leukemia).”
About this source
GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 219 changes logged to date.
What changed
The USPTO published patent application US20260109777A1 covering methods of treating CD20-positive B cell proliferative disorders via subcutaneous administration of mosunetuzumab as monotherapy or in combination with lenalidomide. The application was filed on June 25, 2025 and published April 23, 2026 under CPC classifications including C07K 16/2887 and A61P 35/00.
For pharmaceutical manufacturers and biotech firms developing antibody therapeutics for hematologic malignancies, this published application signals potential future patent claims around subcutaneous delivery formulations and dosing regimens for CD20-targeting agents. Companies should monitor the prosecution of this application to assess freedom-to-operate implications for competing B cell disorder therapies. The application naming 17 inventors across multiple institutions indicates a broad collaborative development effort.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
METHODS OF TREATING CANCER USING SUBCUTANEOUS DOSING OF MOSUNETUZUMAB AS A MONOTHERAPY OR IN COMBINATION WITH LENALIDOMIDE
Application US20260109777A1 Kind: A1 Apr 23, 2026
Inventors
Samuel Dean TRACY, Hong WANG, Jue WANG, Brendan Christian BENDER, Yi Meng CHANG, Iraj HOSSEINI, Chi-Chung LI, Carol Elaine O'HEAR, Juliana Marques Lagrasta BIONDO, Nai Shun YAO, Ian W. FLINN, John M. BURKE, Michael Ching-sun WEI, Mei Shan WU, Antonia Pui-Yue KWAN, Yong Jun MUN
Abstract
The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas or chronic lymphocytic leukemia). More specifically, the invention pertains to the treatment of subjects having a B cell proliferative disorder by subcutaneous administration of mosunetuzumab as a monotherapy or in combination with lenalidomide.
CPC Classifications
C07K 16/2887 A61K 9/0019 A61K 9/0053 A61K 31/138 A61K 31/167 A61K 31/454 A61K 31/573 A61P 35/00 C07K 16/2809 C07K 16/2866 A61K 2039/505 A61K 2039/54 A61K 2039/545 C07K 2317/31
Filing Date
2025-06-25
Application No.
19249597
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.